Navigation Links
Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
Date:2/2/2009

Contract Negotiation is Leading Factor in Improving Formulary Placement of Newer Entrants to Antidiabetic Market, According to a New Report from HealthLeaders-InterStudy and Fingertip Formulary

NASHVILLE, Tenn. and GLEN ROCK, N.J., Feb. 2 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that less than two-thirds of surveyed pharmacy directors expect to reimburse both Bristol-Myers Squibb/AstraZeneca's Onglyza and Takeda's alogliptin once they become available. Sixty-two percent of surveyed pharmacy directors say they expect their managed care organization to reimburse both products, while 26 percent say they expect their organization to reimburse only one. Seventy-eight percent of surveyed pharmacy directors say it is either likely or very likely they will reimburse Novo Nordisk's Victoza upon FDA approval.

According to the new Formulary Forum report entitled Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands, 62 percent of surveyed pharmacy directors say their managed care organization would place Onglyza or alogliptin on Tier 1 or 2 if the agent were priced at $4.00 per treated day, but fewer (24 percent) would place it on Tier 1 or 2 if priced at $5.00 per treated day.

The report also finds that more surveyed pharmacy directors say that contract negotiations are important when improving the formulary position of Merck's Januvia and Amylin/Eli Lilly's Byetta than say safety or efficacy gains leading to downstream cost savings. Both recent entrants in the antidiabetic market, Januvia and Byetta are covered on 85 percent of health plans.

"Our survey reveals that contracting is a leading factor for pharmacy directors looking at products in the antidiabetic market," said Michael Malecki, Ph.D., business analyst with HealthLeaders-InterStudy. "Determining the optimal pricing 'sweet spot' will be important to drive uptake of emerging agents."

About Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations (MCO). Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows easy visualization of data and easy incorporation of material into presentations.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. The company offers a variety of unique data and marketing solutions that provide access to and insight into formulary data for the pharmaceutical industry, consultants and healthcare providers. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

For more information, contact:

    Lisa Osgood                             Elizabeth Marshall
    HealthLeaders-InterStudy                Decision Resources, Inc.
    781-296-2606                            781-296-2563
    losgood@hl-isy.com                      emarshall@dresources.com

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE HealthLeaders-InterStudy; Fingertip Formulary
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
2. Survey: Two-thirds of Illinois public schools provide comprehensive sex education
3. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
4. UNC study: Two-thirds of severe sports injuries to female students due to cheerleading
5. Almost Two-Thirds of Americans Meet Exercise Guidelines
6. Despite Availability of Generic Equivalents, Two-Thirds of Neurologists Will Continue to Prescribe Branded Anti-Epileptic Drugs to Epilepsy Patients
7. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
8. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
9. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
10. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
11. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National ... preparation programs. The NCTQ report suggests, based on a review of GPA and SAT/ACT ... teacher quality in the U.S. It argues that this higher bar should be set ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to improving ... health departments have been awarded national accreditation through the Public Health Accreditation ... expanding network of communities across the nation whose health departments meet rigorous national ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, ... Broadway Avenue, will be an educational and exciting program providing busy clinicians and ... of chronic pain. , Oklahoma is in a healthcare crisis. The state ranks ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... services firm serving the families and businesses of the Norwalk and Vermillion ... Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse prevention ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... to 2022" report to their offering. ... The global wound care market was worth $24,482.9 million ... 6.7% during 2016-2022 Among the various wound care products type, ... global market in 2015. Among the various applications, surgical wound segment held ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology: